AG
RNAC icon

Advisor Group’s Cartesian Therapeutics RNAC Stock Holding History

Advisor Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2K Hold
33
– – ﹤0.01% 5011
2019
Q3 		$2K Hold
33
– – ﹤0.01% 4994
2019
Q2 		$2K Buy
+33
New +$2.25K ﹤0.01% 4999

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Advisor Group's RNAC Position: Q4 2019 in Review

Advisor Group held its Cartesian Therapeutics (RNAC) position steady in Q4 2019 at 33 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5011.

Advisor Group first reported a position in RNAC in Q2 2019 and has held it in 3 quarters since. 38 funds tracked by Wall St. Rank hold RNAC as of Q4 2019.

  • Advisor Group held 33 shares of Cartesian Therapeutics worth $2K as of Q4 2019.
  • Advisor Group left its Cartesian Therapeutics share count unchanged in Q4 2019.
  • Cartesian Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5011 holding.
  • Advisor Group first reported a position in Cartesian Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • 38 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.